Abstract:Purpose. Human pregnane X receptor (hPXR) has a key role in regulating metabolism of endogenous and exogenous substances. Identification of novel hPXR activators among commercial drugs aids in avoiding drug-drug interactions with future co-administered drugs. Methods. Virtual screening with Structure-Activity Relationship (SAR) models has been applied for identification of novel hPXR activators. Ligand-based modeling was conducted with Discover Studio (DS) 2.1. Bayesian classification models were generated with a training set comprising 177 compound, and were validated with a test set with 145 compounds. The activities of commonly prescribed drugs from SCUT database were predicted with one of the Bayesian models. Cell-based luciferase reporter assay was used for evaluation of chemical-mediated hPXR activation. HepG2 cells were co-transfected with PXR expression vector and CYP2B6-luciferase reporter construct. 0.1% DMSO solution was used as vehicle control while rifampicin as the positive control. The binding mode between an experimental validated hPXR modulators and hPXR were studied by docking a ligand into hPXR binding domain (PDB ID: 1NRL) with programs FlexX and SurFlex. Results. The Bayesian models showed specificity and overall prediction accuracy up to 0.92 and 0.69 for test set compounds. One Bayesian model with specificity of 0.92 was selected to screen the SCUT database and retrieved 113 hits. 17 compounds were chosen for in vitro testing. The luciferase reporter assay confirmed that seven drugs, i.e., fluticasone, nimodipine, nisoldipine, beclomethasone, finasteride, flunisolide, and megestrol were previously unidentified potent or moderate hPXR activators, with 2.7 to 18.5- fold increase in luciferase activity compared to vehicle control. Conclusion. In this study, virtual screening based on SAR models successfully identified seven novel hPXR activators among FDA approved and commonly prescribed drugs. The same approach could be used for identification of activators or inhibitors of other protein targets.

LASSO-ing Potential Nuclear Receptor Agonists and Antagonists: A New Computational Method for Database Screening

Virtual Screening of Potentially Endocrine-Disrupting Chemicals Against Nuclear Receptors and Its Application to Identify PPARγ-bound Fatty Acids

Identification of Hpxr Modulators Via Sar-Based Virtual Screening

Identification and Validation of Novel Human Pregnane X Receptor Activators among Prescribed Drugs Via Ligand-Based Virtual Screening

Predicting selective liver X receptor β agonists using multiple machine learning methods.

In Silico Prediction of Estrogen Receptor Subtype Binding Affinity and Selectivity Using Statistical Methods and Molecular Docking with 2-Arylnaphthalenes and 2-Arylquinolines

A De Novo Substructure Generation Algorithm for Identifying the Privileged Chemical Fragments of Liver X Receptorβ Agonists

Novel Estrogen Receptor Ligands and Their Structure-Activity Relationship Evaluated by Scintillation Proximity Assay for High-Throughput Screening

A High-Throughput, Computational System to Predict if Environmental Contaminants Can Bind to Human Nuclear Receptors

In silico prediction of pregnane X receptor activators by machine learning approaches.

Absorption, Distribution, Metabolism, Excretion, and Toxicity Evaluation in Drug Discovery. 14. Prediction of Human Pregnane X Receptor Activators by Using Naive Bayesian Classification Technique.

Development of a Robust Read-Across Model for the Prediction of Biological Potency of Novel Peroxisome Proliferator-Activated Receptor Delta Agonists

Interpretable machine learning for the identification of estrogen receptor agonists, antagonists, and binders

Identifying novel aryl hydrocarbon receptor (AhR) modulators from clinically approved drugs: In silico screening and In vitro validation

In Silico Identification of Small Molecules As Novel LXR Agonists for the Treatment of Cardiovascular Disease and Cancer

Finding the Molecular Scaffold of Nuclear Receptor Inhibitors Through High-Throughput Screening Based on Proteochemometric Modelling

Prediction of binding affinity for estrogen receptor α modulators using statistical learning approaches

Identification of Estrogen Receptor α Antagonists from Natural Products via In Vitro and In Silico Approaches.

Discriminating Functional and Non-Functional Nuclear-Receptor Ligands with a Conformational Selection-Inspired Machine Learning Algorithm

Identify Liver X Receptor Β Modulator Building Blocks by Developing a Fluorescence Polarization-Based Competition Assay.

Discovery of Novel Androgen Receptor Ligands by Structure-based Virtual Screening and Bioassays